Realizing the potential of a powerful tool
Kinase medicines are designed to block the activity of protein kinases: enzymes that regulate critical biochemical pathways in cell growth, survival, metabolism and immune activity. Medicines that can target disease-driving kinases are powerful tools in treating cancer and other diseases.
Today, more than 30 kinase medicines are approved by the U.S. Food and Drug Administration. However, these medicines target less than 5% of the 518 known kinases, and the function of most kinases remains unknown. Many early-generation kinase inhibitors also have significant limitations: due to non-selective activity against multiple kinases, these inhibitors are often associated with dose-limiting toxicities as well as suboptimal target inhibition that may contribute to the emergence of resistance.
Next-generation, selective kinase medicines
Our proprietary scientific platform enables us to rapidly and reproducibly design medicines that selectively target kinase drivers of disease, enabling improved potency, less off-target activity and an increased probability of clinical success.
Avapritinib is a KIT and PDGFRA inhibitor for indolent systemic mastocytosis (SM), advanced SM and a subset of patients with advanced GIST.
Pralsetinib is a RET inhibitor for certain advanced RET fusion-positive solid tumors.
Kinome illustrations reproduced courtesy of Cell Signaling Technology, Inc. (CSTI).
A focused strategy
Our research focuses on kinase targets where we believe our technology can lead to meaningful improvements in treatment.
Difficult-to-drug
Well-recognized kinases that are difficult to target with existing technologies
Treatment-resistant
Mutant kinases that have become resistant to current treatments
Novel biology
New targets identified with our computational and cell biology expertise